Profitability
Weight: 25%
D-
30
- 5yr Avg ROIC -5.7%
- Operating Margin Trend +78.52 pp/yr
PTGX
Protagonist Therapeutics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a platform & compounding fcf business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -6.1%
- 5yr Share-Count CAGR 8.2%
Growth Quality
Weight: 25%
C
55
- 5yr Revenue CAGR 13.9%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
D-
28
- 5yr FCF Margin -152.4%
- 5yr FCF/NI Conversion 0.66x
Balance Sheet
Weight: 10%
C
55
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) 30.00x
- Altman Z-Score 90.68
Stability
Weight: 5%
C+
58
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 1
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 new buy; 1 trimmed; 2 full exits.
- Holders
- 3
- Avg Δ position
- -1.0%
- New buys
- 1
- Full exits
- 2